The FDA EUA submission is based on an interim analysis of efficacy and safety data from the Phase 3 COMET-ICE ... Mar 27
... Mar 16
The new agreement covers 1.25 million additional doses of the casirivimab and imdevimab antibody cocktail, bringing the total potential U.S. supply to over ... Jan 13
The first consignment of the COVID-19 vaccine received by several states in India... Jan 13
India's civil aviation regulator, the Directorate General of Civil Aviation (DGCA), has issued guidelines to airlines and other aircraft operators for transportation of Covid-... Jan 09
State Health Minister, Rajesh Tope said that the dry run will be conducted at three healthcare centers in each district and one center in municipal ... Jan 08
Karnataka Minister for Health and Medical Education Dr. K. Sudhakar has come forward to negate suspicion on the Covaxin vaccine developed by Bharat Biotech.... Jan 05
The government has said that the Covid-19 vaccines introduced in India will be as effective as any vaccine developed by other countries. ... Jan 04
All India Institute of Medical Sciences (AIIMS) Director Dr. Randeep Singh Guleria has lauded the work done by Indian laboratories in making indigenous vaccines.... Jan 04
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material ... Jan 02
India has approved the COVID-19 vaccine developed by AstraZeneca and Oxford University, paving the way for a huge immunization campaign in the world’s ... Jan 02
The results also show that opaganib inhibits SARS-CoV-2 virus replication and proinflammatory markers in relevant preclinical models ... Dec 17
The data will be further analyzed to determine any potential impact on other studies of ruxolitinib in patients with COVID-19, and will be submitted ... Dec 15
PureTech’s global, randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults ... Dec 05
Zydus Cadila, had received an approval from the Drugs Controller General of India to start the Phase 3 clinical trial in COVID-19 patients with ... Dec 04
This test may help identify recovering patients who could potentially be serum and plasma donors for developing treatments for COVID-19... Dec 03
COLCORONA is a non-contact, home, randomized, double-blind, placebo-controlled study conducted in Canada, the United States, Europe, South America, and South Africa... Nov 30
ARCA believes that AB201 is the only anticoagulant class new chemical entity in development for COVID-19 that has a Fast Track designation... Nov 24
The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis ... Nov 23
Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020... Nov 23
The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
Currently no evidence that it improves survival and other important measures ... Nov 20
Monoclonal antibody leads for COVID-19: A way forward In combating COVID-19 ... Nov 19
Researchers say, fluvoxamine may be having beneficial effects by some other mechanism not yet understood... Nov 17
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
